============================================ Tissue Engineering & Stem Cell Research 2005 12th and 13th January 2005 Marriot Kensington Hotel, London ============================================
**** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST YOURS TODAY ****
Visiongain Conferences are please to announce their next conference within the pharmaceutical sector; 'Tissue Engineering & Stem Cell Research 2005'. Stem cell therapy offers an opportunity to treat many degenerative diseases caused by the premature death or malfunction of specific cell types and the body's failure to replace or restore them. This conference will cover the main disease areas where progress in stem cell research is taking place along with a huge emphasis on regional regulatory issues.
THEMES WILL INCLUDE: **Identify new routes to enter the market **Discover key market segments and profit from emerging trends in stem cell therapies **An update on stem cell therapies: CASE STUDIES on treating- spinal cord injuries, kidney disease, gastrointestinal cancers, neurological diseases, myocardial and tooth regeneration **Analyse manufacturing practices and learn how to overcome the challenges in tissue engineering **Become up-to-date on regulatory issues: a global and US perspective **Business Development: commercialisation for drug discovery and cell therapy
KEY SPEAKERS **Dr. Jane Lebkowski, Senior Vice President, Regenerative Medicine, Geron **Julie Gruber Allickson, Technical Director - Laboratory Operations, Cryo-Cell International **Dr. Stephen Minger, Scientific Director/ Director of the Stem Cell Biology Laboratory, CereStem Ltd/ KCL **Dr. Christopher Bravery, Senior Scientist/Team Leader, Intercytex Limited **Larry Soler, Vice President of Government Relations, Juvenile Diabetes Research Foundation International **Dr. Sara Patel, Head of NeuroImaging Group, ReNeuron **Dr. Karl Willert, Postdoctoral fellow, Stanford University Medical Center **Dr Phil Bates, Lecturer in Medical Law, Centre for Medical Law and Ethics, Kings College London **Dr Chris Potten, Chairman, Epistem **David Hill, Scientific Director, Lawson Health Research Institute **Dr. Lior Gepstein, Head Cardiovascular Research Laboratory, Technion-Israel Institute of Technology **Professor Paul Sharpe, Head of Craniofacial Development, Odontis Ltd / King's College London **Professor Jon Dobson,Professor of Biophysics & Biomedical Engineering , Keele University **Professor Alicia El Haj, Institute of Science & Technology in Medicine, Keele University **Dr. Richard France, Project Manager, RegenTec Ltd **Professor Harry Moore, Director/ Centre for Stem Cell Biology, Axordia/ University of Sheffield
------------------ WHO SHOULD ATTEND ------------------
**Senior Vice President, Regenerative Medicine **Research Director for Assisted Reproduction and Embryonic Stem Cells **Vice President, Technology **Vice President, Therapeutic Development Operations **Director, Experimental Medicine **Vice President of Government Relations **Vice President Clinical Affairs, & Director **Vice President, Product Development **Business Development Manager
--------------------- DELEGATE REGISTRATION ---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW. To make a booking on this event, please contact me via phone or email. Book early to secure a place.
- PRICING -
Attend the: 2 Day conference - ONLY GBP1299 plus VAT
- BOOKINGS -
Booking is easy, simply contact me:
Andrew Oliver Sales Manager - Conference Division Visiongain B2B Conferences Tel. +44(0)20 8767 6711 Fax. +44(0)20 8767 5001 mailto:andrew.oliver@visiongaingroup.com www.b2b-conferences.com
B2B Conferences is part of the Visiongain Group
**** FULL CONFERENCE AGENDA BELOW ****
==================================== Day One Wednesday 12th January 2005 ====================================
09:00 Registration and coffee
09:30 Opening remarks from the chair
AN UPDATE ON STEM CELL THERAPIES
09:40 CASE STUDY: Advances in Stem Cell Programs- Treating Spinal Cord Injuries How to penetrate the emerging field of regenerative medicine Oligodendrocyte progenitors- can they restore normal neural function? - results in animal models: significant functional improvements Progress in phase I clinical trials: focus on treatment for acute spinal cord injury Technologies in this field- licenses and intellectual property Dr. Jane Lebkowski, Senior Vice President, Regenerative Medicine Geron
10:20 CASE STUDY: Metanephroi Transplantation- Treating Kidney Disease How to develop normal renal structures by transplanting kidney precursors Transplanting between species without rejection- how to ensure minimal immunosupression, leading to success Conclusions: implanted metanephroi have intrinsic ability to continue developing and organising into functional tissue structures Advantages over renal transplant or dialysis: - better clinical outcome than intermittent dialysis, as filtration is continuous and active - unlimited supply of organs available by this procedure Dr. Christopher Bravery, Senior Scientist/Team Leader Intercytex Limited
11:00 Morning Coffee
11:20 CASE STUDY: in vitro and in vivo Model Systems- Treating Gastrointestinal Cancers in vivo models: using the in situ tumour model ADENOQUANT to directly compare tumour and normal tissue responses and assess therapeutic index Transgenic and xenograft models: how to determine the importance of gene pathways and treatment response in GI tissue in vitro screening assay: PRIMEQUANT to realistically predict the in vivo response and allow accurate comparisons of normal and matched tumour tissue biology How to use assays to assess stem cell regulatory effects to hyper- and hypoplasia therapies, wound healing agents and mucositis therapies Professor Chris Potten, Chairman Epistem
12:00 CASE STUDY: Development of islets from precursor cells in vitro and in vivo Generation of insulin-producing cells from embryonic stem cells or hematopoeitic stem cells Trans-differentiation capabilities of other pancreatic cell types to islets Barriers to clinical application Mechanisms of regeneration of islets in vivo David Hill, Scientific Director Lawson Health Research Institute
12:40 Lunch
14:00 Can Human Brain Cell Transplantation treat Neurological Diseases? Assess advantages and disadvantages of immortalised stem cell lines c-Myc gene cell lines: transplant strategies Graft effects in animal models of neurodegenerative diseasefunctional and structural integration How to use stem cells as a platform technology for drug discovery - identifying small molecules or proteins to mature a brain stem cell into a differentiated cell - stem cells for screening potential lead compounds for toxicity Dr. Sara Patel, Head of NeuroImaging Group ReNeuron
14:40 Myocardial Regeneration Strategies using Human Embryonic Stem Cells Heart cells from human embryonic stem cells- progress to date - derivation, in vitro differentiation and implications for basic research & clinical applications How to use it- development and testing of new drugs, genetic studies, engineering tissues, organ transplantation, study purposes Myocardial regeneration strategies- replacing the dysfunctional myocardium with new contractile tissue Regulations in Israel- looking to the future in research Dr. Lior Gepstein, Head Cardiovascular Research Laboratory Technion-Israel Institute of Technology
15:20 Afternoon Tea
15:40 CASE STUDY: Regenerative Dentistry- How to Grow a Tooth How to understand and genetically control the key processes forming teeth in the embryo Interactions between epithelial and mesenchymal cells - how to culture cells to form primordia Results from mice populations- tooth rudiments formed from in vitro cultures of non-dental stem cell populations Can rudiments be transferred to adults? - formation of complete teeth and associated bones Professor Paul Sharpe, Head of Craniofacial Development Odontis Ltd / King's College London
MANUFACTURING PRACTICES: CHALLENGES IN TISSUE ENGINEERING
16:20 Implications of GTP/GMP for Cord Blood Processing Moving from Clean Lab to an ISO class 7 Cleanroom Environment How the FDA's proposed GTP affects cell processing Future Direction: cord blood processing - regulatory impacts Julie Gruber Allickson, Technical Director - Laboratory Operations Cryo-Cell International
17:00 Questions and Discussion
17:10 Chairman Summation
17:20 Close of Conference
=================================== Day Two Thursday 13th January 2005 ===================================
09:00 Registration and coffee
09:30 Opening remarks from the chair
An Overview of the Industry The panel session at the end of Day Two will offer you the chance to hear from Ray Scraggs, Head Consultant at visiongain on the most detailed and accurate market information available on Tissue Engineering and Stem Cell Research. 09:40 Advances in Tissue Regeneration: Human ES Cells, Growth Factors and Biotherapeutic Molecules
The sources of stem cell and ES cells- learn about the benefits of stem cell technology Cell nuclear replacement: the fight against type 1 diabetes and Parkinson's disease Exploiting novel growth factors: promoting the proliferation and lineage-specific propagation of stem cell populations Dr. Stephen Minger, Scientific Director/ Director of the Stem Cell Biology Laboratory CereStem Ltd/ King's College London
10:20 Magnecell's Mechanical Conditioning Bioreactor Systems: How to Activate Ion Channels Update on ex-vivo bone engineering results - speed of matrix mineralisation; regulation of genes involved in bone growth Patent technologies for tissue engineering: mechanisms for ex-vivo simulation of the in-vivo stress environment Applications of system: drug screening, in-vitro testing and stem cell research Future areas for growth: ex-vivo magnetic activation of in-vivo cellular processes Professor Jon Dobson, Professor of Biophysics & Biomedical Engineering/ Co-Founder and Technical Advisor Keele University/ Magnecell Limited
11:00 Morning Coffee
11:20 Biodegradable scaffolds - Delivery systems for Cell Therapies Osteochondral and corneal repair using cell therapies and tissue engineering approaches Delivery vehicles and biodegradable scaffolds for cell therapies Scaffold design and in vitro and in vivo tissue engineering strategies Stem Cell targeting Professor Alicia El Haj, Institute of Science & Technology in Medicine Keele University
12:00 Self Assembling and Injectable Materials for Regenerative Medicine Injectable biodegradable scaffolds for cell and growth factor delivery Crosslinking strategies for scaffold self assembly Controlling macroporosity within the scaffold environment Dr. Richard France, Project Manager RegenTec Ltd
12:40 Lunch
14:00 Stem Cell Maintenance: Results from Isolating the Wnts Protein Potential of isolating Wnt proteins- can stem cells be used for bone marrow transplants? Wnt signaling: a common theme in animal development How do Wnt proteins cause hematopoietic stem cells to divide? Analysis: pathways triggering stem cell growth Dr. Karl Willert, Postdoctoral Fellow Stanford University Medical Center
REGULATORY ISSUES
14:40 Global Perspective: Legal Framework for Stem Cell Research Global situation: US Federal ban on all bar 60 stem cell lineseffects on federally-funded research and privately funded research What is the legal framework for research in the UK? Lack of a co-ordinated global policy: effects on research Better results from stem cells derived from bone marrow and the placenta than embryonic stem cells Dr Phil Bates, Lecturer in Medical Law Centre for Medical Law and Ethics Kings College London
15:20 Afternoon Tea
15:40 Regulation in the US: Expanding the Current Federal Policy on Stem Cell Research The "Stem Cell Research Enhancement Act of 2004" Problems with the existing policy and proposed changes to overcome them Is adult stem cell research a feasible alternative? California's Proposition 71- update on progress Slowing down research- JDRF perspective Larry Soler, Vice President of Government Relations Juvenile Diabetes Research Foundation International
BUSINESS DEVELOPMENT
16:20 Human Embryonic Stem Cells: Commercialisation for Drug Discovery and Cell Therapy Cell lines and quality assurance the challenge of generating GMP ES cell lines Regulating proliferation and plurioptency Markers of differentiation Production platforms Professor Harry Moore, Director/ Centre for Stem Cell Biology Axordia/ University of Sheffield
17:00 Discussion: Attendees Perspective
Presentation and discussion by Dr. Ray Scraggs of the previous days questionnaire results. An insight will be given into the market revenues, growth areas, new developments and new entrants to the Tissue Engineering and Stem Cell Research industry. This will involve some freeform discussion giving you the opportunity to engage in knowledge-sharing with fellow professionals Moderator: Dr. Ray Scraggs, Head Consultant visiongain Consultancy
17:20 Question and Discussion
17:30 Chairman Summation
17:30 Close of Conference
Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.